23andMe Holding Co. is a pharmaceutical company based in the United States that specializes in consumer-facing healthcare technology. They offer direct-to-consumer personal genome services (PGS) through DNA collection kits sent via mail. Users can access reports on genetic ancestry, phenotypic traits, health predispositions, and disease carriers. With a medium risk ESG score of 21.4, the company's segments include Consumer and Research Services and Therapeutics, with a focus on revenue generation from the former.